VALNAC Drug Patent Profile
✉ Email this page to a colleague
When do Valnac patents expire, and when can generic versions of Valnac launch?
Valnac is a drug marketed by Actavis Mid Atlantic and is included in one NDA.
The generic ingredient in VALNAC is betamethasone valerate. There are sixty-six drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the betamethasone valerate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Valnac
A generic version of VALNAC was approved as betamethasone valerate by FOUGERA PHARMS INC on August 31st, 1983.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VALNAC?
- What are the global sales for VALNAC?
- What is Average Wholesale Price for VALNAC?
Summary for VALNAC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 64 |
| Patent Applications: | 5,233 |
| DailyMed Link: | VALNAC at DailyMed |
Pharmacology for VALNAC
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
US Patents and Regulatory Information for VALNAC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actavis Mid Atlantic | VALNAC | betamethasone valerate | CREAM;TOPICAL | 070050-001 | Oct 10, 1984 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
